Antidepressants for bipolar depression: a systematic review of randomized, controlled trials.

@article{Gijsman2004AntidepressantsFB,
  title={Antidepressants for bipolar depression: a systematic review of randomized, controlled trials.},
  author={Harm J. Gijsman and John R. Geddes and Jennifer M. Rendell and Willem A. Nolen and Guy M. Goodwin},
  journal={The American journal of psychiatry},
  year={2004},
  volume={161 9},
  pages={
          1537-47
        }
}
OBJECTIVE This study reviewed the evidence from randomized, controlled trials on the efficacy and safety of antidepressants in the short-term treatment of bipolar depression. METHOD The authors performed a systematic review and meta-analysis of randomized, controlled trials. They searched the Cochrane Collaboration Depression, Anxiety, and Neurosis Controlled Trials Register, incorporating results of searches of MEDLINE, EMBASE, CINAHL, PsycLIT, PSYNDEX, and LILACS. The main outcome measures… Expand
Antidepressants for bipolar disorder: A meta-analysis of randomized, double-blind, controlled trials
TLDR
Existing evidence of efficacy does not support the short-term or long-term application of antidepressant therapy in patients with bipolar disorder, although the tolerability and safety of antidepressants have been generally acknowledged. Expand
Treatment Options for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials
TLDR
Variability in efficacy exists between treatments of bipolar depression, and quetiapine and the olanzapine-fluoxetine combination showed the greatest symptomatic improvement. Expand
[The pharmacological treatment of bipolar disorder: a systematic and critical review of the methodological aspects of modern clinical trials].
  • E. Cheniaux
  • Psychology, Medicine
  • Revista brasileira de psiquiatria
  • 2011
TLDR
All drugs currently indicated for mania, bipolar depression and maintenance treatment of bipolar disorder were more effective than placebo in at least one clinical trial. Expand
A systematic review of the evidence for the treatment of acute depression in bipolar I disorder
TLDR
Evidence for the acute treatment of depression in bipolar I disorder is examined, focusing on double-blind, placebo-controlled studies with a definite primary outcome measure and published in peer review journals, to better understand the role of antidepressants. Expand
Review of evidence for use of antidepressants in bipolar depression.
TLDR
The recommendations from evidence-based guidelines do not support antidepressant monotherapy for bipolar depression, and only when mood stabilizer or atypical antipsychotic monotherapy has failed should adjunctive treatment with an antidepressant be considered. Expand
Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis.
TLDR
Valproate is effective for the reduction of depressive symptoms of acute bipolar depression, and was well tolerated. Expand
Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review
TLDR
Mood stabilisers are moderately efficacious for acute bipolar depression and combination therapy was not statistically superior to monotherapy. Expand
An update on the treatment of bipolar depression
TLDR
A practice-based suggestion, valuable for both short- and long-term treatment, might be to have a background of mood stabilizers and to add drugs, following one of several treatment options, trusting to find a drug with a degree of effectiveness by trial and error. Expand
Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis.
TLDR
These results could serve evidence-based practice and inform patients, physicians, guideline developers, and policymakers on the relative benefits of the different antidepressants, antipsychotics, and mood-stabilizing agents for the treatment of bipolar depression. Expand
Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials
TLDR
There is evidence from placebo-controlled trials for the efficacy of lithium, valproate and lamotrigine as maintenance therapy for the prevention of relapse in bipolar disorder and the strength of evidence was not equal for all treatments or for all comparisons. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 56 REFERENCES
Treatment of depression in bipolar disorder: new directions for research.
TLDR
There are few studies of treatment of the depressed phase of bipolar disorder, and their results generally are limited or inconclusive, but limited data on other antidepressant classes suggest that monoamine oxidase inhibitors, bupropion, and serotonergic agents may offer some advantages over tricyclic antidepressants in this population. Expand
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
TLDR
Continuing treatment with antidepressants in patients with depressive disorders who have responded to acute treatment reduced the odds of relapse by 70% and seemed to persist for up to 36 months, although most trials were of 12 months' duration, and so the evidence on longer-term treatment requires confirmation. Expand
A double-blind trial of bupropion versus desipramine for bipolar depression.
TLDR
A prospective double-blind trial to assess efficacy and rate of treatment-emergent mood elevation in depressed bipolar patients when bupropion or desipramine was added to an ongoing therapeutic regimen of lithium or an anticonvulsant suggests that bupropions is less likely to induce mood elevation than desipramsine. Expand
Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression.
TLDR
Antidepressants may not be useful adjunctive therapy for bipolar depressed patients with high serum lithium levels or who have symptoms that are refractory to the antidepressant effects of lithium, but both paroxetine and imipramine were superior to placebo for patients with low serum lithium Levels. Expand
The treatment of bipolar depression.
TLDR
Of the antidepressants, bupropion and the selective serotonin reuptake inhibitors may be associated with less risk of inducing hypomania, mania, and rapid cycling compared with tricyclic antidepressants. Expand
A double- Blind placebo-controlled study of lamotriqine monotherapy outpatients with bipolar I depression
TLDR
Lamotrigine monotherapy is an effective and well-tolerated treatment for bipolar I depression and demonstrates significant antidepressant efficacy on the 17-item Hamilton Rating Scale for Depression and MADRS compared with placebo. Expand
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
TLDR
Olanzapine is more effective than placebo, and combined olanzapine-fluoxetine isMore effective than olanZapine and placebo in the treatment of bipolar I depression without increased risk of developing manic symptoms. Expand
A double-blind study comparing idazoxan and bupropion in bipolar depressed patients.
TLDR
Preliminary findings suggesting the usefulness of idazoxan in bipolar depression, larger more rigorous studies are indicated. Expand
A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers.
TLDR
Paroxetine and venlafaxine are both effective and safe in the treatment of depressive breakthrough episodes in bipolar disorder and there was a suggestion of a slightly higher risk for switch to mania or hypomania with venl Lafaxine. Expand
Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode.
  • J. Amsterdam
  • Psychology, Medicine
  • Journal of clinical psychopharmacology
  • 1998
TLDR
Preliminary findings suggest that short-term, 6-week venlafaxine treatment may be a safe and effective antidepressant monotherapy for BP II major depression. Expand
...
1
2
3
4
5
...